Zacks Investment Research cut shares of Clinigen Group Plc (NASDAQ:CLIGF) from a buy rating to a hold rating in a report published on Tuesday.

According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “

Shares of Clinigen Group Plc (NASDAQ CLIGF) opened at 13.90 on Tuesday. Clinigen Group Plc has a 12 month low of $8.70 and a 12 month high of $13.90. The firm has a market cap of $1.60 billion and a P/E ratio of 86.34.

COPYRIGHT VIOLATION WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at

Get a free copy of the Zacks research report on Clinigen Group Plc (CLIGF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Clinigen Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.